Phase 2 trial of neoadjuvant camrelizumab plus chemotherapy for locally advanced esophageal squamous cell carcinoma

Camrelizumab and chemotherapy demonstrated durable antitumor activity with a manageable safety profile as first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). A multicenter phase 2 trial in China evaluated the safety and efficacy of the combination of camrelizumab plus chemotherapy as neoadjuvant treatment for locally advanced ESCC. The study found robust antitumor activity of the combination, allowing R0 resection in 50 of 51 patients undergoing surgery (98.0%). There were no unexpected safety signals.